{
    "clinical_study": {
        "@rank": "121121", 
        "arm_group": [
            {
                "arm_group_label": "FIAsp", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days"
            }, 
            {
                "arm_group_label": "NovoRapid\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate the\n      pharmacokinetic (the exposure of the trial drug in the body) properties of FIAsp\n      (faster-acting insulin aspart) in children, adolescents and adults with type 1 diabetes."
        }, 
        "brief_title": "A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female aged 6-64 years (both inclusive) at the time of signing informed\n             consent\n\n          -  Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months\n\n          -  Body mass index (BMI) for children and adolescents (male and female) between the 3rd\n             and 97th BMI percentile and for adults equal to or below 28.0 kg/m^2\n\n        Exclusion Criteria:\n\n          -  Subject who has donated any blood or plasma in the past month or more than 500 mL\n             within 3 months prior to screening\n\n          -  Smoker (defined as a subject who is smoking at least one cigarette, cigar or pipe\n             daily)\n\n          -  Not able or willing to refrain from smoking and use of nicotine substitute products\n             during the inpatient period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "39", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02035371", 
            "org_study_id": "NN1218-3888", 
            "secondary_id": [
                "2011-002104-32", 
                "U1111-1121-1469"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "FIAsp", 
                "description": "A single dose will be administered subcutaneously (s.c. under the skin)", 
                "intervention_name": "insulin aspart (FIAsp)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "NovoRapid\u00ae", 
                "description": "A single dose will be administered subcutaneously (s.c. under the skin)", 
                "intervention_name": "insulin aspart", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 14, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Hannover", 
                    "country": "Germany", 
                    "zip": "30173"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Area under the serum insulin aspart concentration-time curve", 
            "safety_issue": "No", 
            "time_frame": "From 0 to 12 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02035371"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Maximum observed serum insulin aspart concentration", 
            "safety_issue": "No", 
            "time_frame": "From 0-12 hours"
        }, 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}